Study on the Clinical Efficacy of Teclistamab
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversitaire Ziekenhuizen KU Leuven
About this trial
The aim of this study is to assess the clinical efficacy and safety of the anti-BCMA/CD3 bispecific antibody teclistamab (Tecvayli®) in a prospective, real-life setting in Belgium.
Eligibility criteria
Qualifiers
Age 18 years or older
Written informed consent
Has a diagnosis of relapsed and refractory multiple myeloma
Has already received at least three previous treatments
Disqualifiers
Has participated in a teclistamab trial (teclistamab or control arm) or teclistamab Single Patient Request (SPR) program
Has started teclistamab treatment >14 days before intended screening visit.
Trial design
Treatments tested in this trial
- Teclistamab
Treatment groups
100 Participants
are divided into 1 treatment groupLocations
17Imelda2820, BonheidenAntwerpen, Belgium
Universitair Ziekenhuis Antwerpen (UZA)2500, EdegemAntwerpen, Belgium
Grand Hôpital de Charleroi6000, CharleroiHenegouwen, Belgium
EpiCURA7301, HornuHenegouwen, Belgium
Sponsors and collaborators
Universitaire Ziekenhuizen KU Leuven
Lead sponsor
Janssen Pharmaceutica
Collaborator
Source ClinicalTrials.gov